US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Latest News about NASDAQ:CADL

Recent news which mentions NASDAQ:CADL

Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation
Tickers CADL DAWN YMAB
Tags NASDAQ:DAWN NASDAQ:YMAB NASDAQ:CADL
From News Direct
CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024
Tickers CADL
Tags NASDAQ:CADL CADL Earnings Reports
From InvestorPlace
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
Tickers CADL
Tags NASDAQ:CADL
From News Direct
Candel Therapeutics’ (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
Tickers CADL
Tags NASDAQ:CADL
From News Direct
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
Tickers CADL
Tags NASDAQ:CADL
From News Direct
CADL Stock Earnings: Candel Therapeutics Reported Results for Q1 2024
Tickers CADL
Tags CADL NASDAQ:CADL Market News
From InvestorPlace
CADL Stock Earnings: Candel Therapeutics Misses EPS for Q4 2023
Tickers CADL
Tags NASDAQ:CADL CADL Market News
From InvestorPlace
Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors
Tickers CADL
Tags NASDAQ:CADL
From News Direct
Moving Fast: Candel’s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer
Tickers CADL
Tags NASDAQ:CADL
From News Direct
Candel Therapeutics Sets Stage For Success With Cancer-Fighting Immunotherapies
Tickers CADL
Tags NASDAQ:CADL
From News Direct